Amicus Therapeutics, Inc. Merger Agreement with BioMarin Pharmaceutical Inc.

Amicus Therapeutics, Inc. has entered into an Agreement and Plan of Merger with BioMarin Pharmaceutical Inc. and its subsidiary, Lynx Merger Sub 1, Inc. The merger will result in Amicus Therapeutics becoming a wholly-owned subsidiary of BioMarin Pharmaceutical. Each share of Amicus common stock will be converted into $14.50 in cash. The transaction is subject to customary closing conditions, including regulatory approvals and stockholder adoption, with an expected closing in the second quarter of 2026. The agreement includes provisions for the treatment of Amicus equity awards, indemnification of officers and directors, and termination fees under certain circumstances. Amicus has also amended its bylaws to include a forum selection clause. The parties have issued a joint press release and distributed various communications to employees, stakeholders, and investors regarding the transaction.